BioSpecifics Technologies (BSTC) recently announced positive top line data from a phase IIa study on Xiaflex for the potential treatment of frozen shoulder syndrome (FSS) in adults. BioSpecifics has a strategic partnership with Auxilium Pharmaceuticals, Inc. (AUXL) for Xiaflex.
The open-label controlled dose-ranging phase IIa study, conducted by Auxilium Pharma, evaluated the safety and efficacy of Xiaflex for the treatment of stage II unilateral idiopathic frozen shoulder in comparison with an exercise-only group.
The study involved 50 adults, equally divided into 5 groups. Four such cohorts received up to three injections of Xiaflex (doses ranging from 0.29 mg to 0.58mg in three different volumes: 0.5, 1.0, or 2.0 mL) in addition to home shoulder exercises. The fifth cohort only performed home shoulder exercises.
Dosing arms – 0.58mg (1mL) and 0.58mg (2mL) – showed statistically significant positive improvement from baseline in forward flexion versus the exercise-only group.
We note that Xiaflex, an injectable enzyme, is already available for the treatment of Dupuytren’s contracture (:DC). DC refers to a condition that affects the connective tissue in the palm known as palmar fascia. BioSpecifics Technologies /Auxillium Pharma are evaluating the drug for other indications also. Xiaflex is currently under FDA review for the Peyronie’s indication (:PD). A response from the agency should be out by Sep 6, 2013.
Both BioSpecifics and Auxilium Pharma carry a Zacks Rank #3 (Hold). Currently, companies like Lannett Company, Inc. (LCI) and WuXi Pharma Tech (Cayman) Inc. (WX) look more attractive with a Zacks Rank #1 (Strong Buy).
Read the Full Research Report on BSTC
Read the Full Research Report on AUXL
Read the Full Research Report on WX
Read the Full Research Report on LCI
More From Zacks.com